Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Konicek DM"'
Autor:
Konicek DM; Insmed Incorporated, Bridgewater, NJ 08807, USA., Plaunt AJ; Insmed Incorporated, Bridgewater, NJ 08807, USA., Gharse S; Insmed Incorporated, Bridgewater, NJ 08807, USA., Rose SJ; Insmed Incorporated, Bridgewater, NJ 08807, USA., Dorfman A; Insmed Incorporated, Bridgewater, NJ 08807, USA., Sabnis A; Insmed Incorporated, Bridgewater, NJ 08807, USA., Baker T; Insmed Incorporated, Bridgewater, NJ 08807, USA., Gauani H; Insmed Incorporated, Bridgewater, NJ 08807, USA., Chun D; Insmed Incorporated, Bridgewater, NJ 08807, USA., Li Z; Insmed Incorporated, Bridgewater, NJ 08807, USA., Perkins WR; Insmed Incorporated, Bridgewater, NJ 08807, USA., Cipolla D; Insmed Incorporated, Bridgewater, NJ 08807, USA., Malinin VS; Insmed Incorporated, Bridgewater, NJ 08807, USA.
Publikováno v:
Pharmaceutics [Pharmaceutics] 2023 Aug 31; Vol. 15 (9). Date of Electronic Publication: 2023 Aug 31.
Autor:
Plaunt AJ, Rose SJ, Kang JY, Chen KJ, LaSala D, Heckler RP, Dorfman A, Smith BT, Chun D, Viramontes V, Macaluso A, Li Z, Zhou Y, Mark L, Basso J, Leifer FG, Corboz MR, Chapman RW, Cipolla D, Perkins WR, Malinin VS, Konicek DM
Publikováno v:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2022 Nov 15; Vol. 66 (11), pp. e0125622. Date of Electronic Publication: 2022 Oct 12.
Autor:
Plaunt AJ; Insmed Incorporated, Bridgewater, New Jersey, USA., Rose SJ; Insmed Incorporated, Bridgewater, New Jersey, USA., Kang JY; Insmed Incorporated, Bridgewater, New Jersey, USA., Chen KJ; Insmed Incorporated, Bridgewater, New Jersey, USA., LaSala D; Insmed Incorporated, Bridgewater, New Jersey, USA., Heckler RP; Insmed Incorporated, Bridgewater, New Jersey, USA., Dorfman A; Insmed Incorporated, Bridgewater, New Jersey, USA., Smith BT; Insmed Incorporated, Bridgewater, New Jersey, USA., Chun D; Insmed Incorporated, Bridgewater, New Jersey, USA., Viramontes V; Insmed Incorporated, Bridgewater, New Jersey, USA., Macaluso A; Insmed Incorporated, Bridgewater, New Jersey, USA., Li Z; Insmed Incorporated, Bridgewater, New Jersey, USA., Zhou Y; Insmed Incorporated, Bridgewater, New Jersey, USA., Mark L; Insmed Incorporated, Bridgewater, New Jersey, USA., Basso J; Insmed Incorporated, Bridgewater, New Jersey, USA., Leifer FG; Insmed Incorporated, Bridgewater, New Jersey, USA., Corboz MR; Insmed Incorporated, Bridgewater, New Jersey, USA., Chapman RW; Insmed Incorporated, Bridgewater, New Jersey, USA., Cipolla D; Insmed Incorporated, Bridgewater, New Jersey, USA., Perkins WR; Insmed Incorporated, Bridgewater, New Jersey, USA., Malinin VS; Insmed Incorporated, Bridgewater, New Jersey, USA., Konicek DM; Insmed Incorporated, Bridgewater, New Jersey, USA.
Publikováno v:
Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2021 Jun 17; Vol. 65 (7), pp. e0031621. Date of Electronic Publication: 2021 Jun 17.
Autor:
Chapman RW; Insmed Incorporated, Bridgewater, NJ, USA., Corboz MR; Insmed Incorporated, Bridgewater, NJ, USA., Fernandez C; Insmed Incorporated, Bridgewater, NJ, USA., Sullivan E; Insmed Incorporated, Bridgewater, NJ, USA., Stautberg A; Insmed Incorporated, Bridgewater, NJ, USA., Plaunt AJ; Insmed Incorporated, Bridgewater, NJ, USA., Konicek DM; Insmed Incorporated, Bridgewater, NJ, USA., Malinin V; Insmed Incorporated, Bridgewater, NJ, USA., Li Z; Insmed Incorporated, Bridgewater, NJ, USA., Cipolla D; Insmed Incorporated, Bridgewater, NJ, USA., Perkins W; Insmed Incorporated, Bridgewater, NJ, USA.
Publikováno v:
ERJ open research [ERJ Open Res] 2021 Feb 15; Vol. 7 (1). Date of Electronic Publication: 2021 Feb 15 (Print Publication: 2021).
Autor:
Chapman RW; Insmed Incorporated, 202/206 North, Bridgewater, NJ, 08807, USA. Electronic address: richard.chapman@insmed.com., Corboz MR; Insmed Incorporated, 202/206 North, Bridgewater, NJ, 08807, USA., Malinin VS; Insmed Incorporated, 202/206 North, Bridgewater, NJ, 08807, USA., Plaunt AJ; Insmed Incorporated, 202/206 North, Bridgewater, NJ, 08807, USA., Konicek DM; Insmed Incorporated, 202/206 North, Bridgewater, NJ, 08807, USA., Li Z; Insmed Incorporated, 202/206 North, Bridgewater, NJ, 08807, USA., Perkins WR; Insmed Incorporated, 202/206 North, Bridgewater, NJ, 08807, USA.
Publikováno v:
Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2020 Dec; Vol. 65, pp. 102002. Date of Electronic Publication: 2021 Feb 15.
Autor:
Leifer FG; Insmed Incorporated, Bridgewater, NJ, USA.; Insmed Incorporated, Bridgewater, NJ, USA.; IPS Therapeutique Inc., Sherbrooke, QC, Canada., Konicek DM; Insmed Incorporated, Bridgewater, NJ, USA.; Insmed Incorporated, Bridgewater, NJ, USA.; IPS Therapeutique Inc., Sherbrooke, QC, Canada., Chen KJ; Insmed Incorporated, Bridgewater, NJ, USA., Plaunt AJ; Insmed Incorporated, Bridgewater, NJ, USA., Salvail D; IPS Therapeutique Inc., Sherbrooke, QC, Canada., Laurent CE; IPS Therapeutique Inc., Sherbrooke, QC, Canada., Corboz MR; Insmed Incorporated, Bridgewater, NJ, USA., Li Z; Insmed Incorporated, Bridgewater, NJ, USA., Chapman RW; Insmed Incorporated, Bridgewater, NJ, USA., Perkins WR; Insmed Incorporated, Bridgewater, NJ, USA., S Malinin V; Insmed Incorporated, Bridgewater, NJ, USA.
Publikováno v:
Drug research [Drug Res (Stuttg)] 2018 Nov; Vol. 68 (11), pp. 605-614. Date of Electronic Publication: 2018 May 23.
Autor:
Chapman RW; Insmed Incorporated, Bridgewater, NJ 08807, USA. Electronic address: richard.chapman@insmed.com., Li Z; Insmed Incorporated, Bridgewater, NJ 08807, USA., Corboz MR; Insmed Incorporated, Bridgewater, NJ 08807, USA., Gauani H; Insmed Incorporated, Bridgewater, NJ 08807, USA., Plaunt AJ; Insmed Incorporated, Bridgewater, NJ 08807, USA., Konicek DM; Insmed Incorporated, Bridgewater, NJ 08807, USA., Leifer FG; Insmed Incorporated, Bridgewater, NJ 08807, USA., Laurent CE; IPS Therapeutique Incorporated, Sherbrooke, QC J1G5J6, Canada., Yin H; IPS Therapeutique Incorporated, Sherbrooke, QC J1G5J6, Canada., Salvail D; IPS Therapeutique Incorporated, Sherbrooke, QC J1G5J6, Canada., Dziak C; Envigo CRS Incorporated, East Millstone, NJ 08873, USA., Perkins WR; Insmed Incorporated, Bridgewater, NJ 08807, USA., Malinin V; Insmed Incorporated, Bridgewater, NJ 08807, USA.
Publikováno v:
Pulmonary pharmacology & therapeutics [Pulm Pharmacol Ther] 2018 Apr; Vol. 49, pp. 104-111. Date of Electronic Publication: 2018 Feb 05.
Autor:
Corboz MR; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.) michel.corboz@insmed.com., Li Z; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Malinin V; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Plaunt AJ; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Konicek DM; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Leifer FG; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Chen KJ; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Laurent CE; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Yin H; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Biernat MC; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Salvail D; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Zhuang J; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Xu F; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Curran A; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Perkins WR; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.)., Chapman RW; Insmed Incorporated, Research & Development, Bridgewater, New Jersey (M.R.C., Z.L., V.M., A.J.P., D.M.K., F.G.L., K.-J.C., W.R.P., R.W.C.); IPS Therapeutique Inc., Sherbrooke, Québec, Canada (C.E.L., H.Y., M.C.B., D.S.); Lovelace Respiratory Research Institute, Pathophysiology Program, Albuquerque, New Mexico (J.Z., F.X.); and Envigo CRS Inc., East Millstone, New Jersey (A.C.).
Publikováno v:
The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2017 Dec; Vol. 363 (3), pp. 348-357. Date of Electronic Publication: 2017 Sep 13.